BUZZ-Dexcom rises as FDA clears use of its 15-day continuous glucose monitor
I'm PortAI, I can summarize articles.
Shares of Dexcomrose 8.6% to $72.60 in premarket trading after the U.S. FDA approved its 15-day continuous glucose monitor, the Dexcom G7. This device is designed for adults with diabetes, offering easier glucose management with fewer sensors and less waste. The approval is expected to drive momentum for the company through 2025, according to brokerage William Blair. Prior to this, the stock had declined 14.1% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments